Darmiyan Inc. is a pioneering company in the field of neurodiagnostics, specializing in the early detection, monitoring, and stratification of neurodegenerative diseases such as Alzheimer's Disease (AD). The company operates in the healthcare and medical technology market, serving healthcare providers, neurologists, and researchers. Darmiyan's core product, BrainSee™, is a Software as a Service (SaaS) platform that utilizes advanced magnetic resonance (MR) image analysis technology to precisely quantify and detect changes in brain tissue at the cellular level. This technology is based on over 40 years of cutting-edge brain research and can analyze standard clinical brain MRI scans (T1, T2 FLAIR, and DWI DTI) within a few hours, providing detailed brain maps with exact quantification of neurodegeneration in each voxel (3D pixel) of a brain MRI scan.

Darmiyan's business model revolves around providing its SaaS platform to medical institutions and professionals on a subscription basis. The company generates revenue through these subscriptions, which offer continuous access to its diagnostic tools and updates. Additionally, Darmiyan may engage in partnerships and collaborations with pharmaceutical companies and research institutions for further development and validation of its technology.

The market for neurodiagnostic tools is growing, driven by an aging population and increasing prevalence of neurodegenerative diseases. Darmiyan's innovative approach positions it well to capture a significant share of this market by offering a non-invasive, accurate, and efficient diagnostic solution.

Keywords: neurodiagnostics, Alzheimer's Disease, MRI analysis, SaaS, brain mapping, neurodegeneration, healthcare technology, early detection, medical imaging, subscription model.